ASX Announcement Cleo Diagnostics Ltd ASX: COV Level 2, 480 Collins Street, Melbourne, VIC, 3000 ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com Directors Chair and Non-Executive Director Adrien Wing Chief Executive Officer and Executive Director Dr Richard...
Quarterly activities and cashflow report
Filed with ASX · · 9 pages · English
Release
Earlier from CLEO Diagnostics
- CLEO Enters Analytical Validation Phase
- CLEO Establishes U.S. Reimbursement Pathway
- CLEO Commences Kit Manufacturing Ahead of FDA Submission
- Sample Collection Completion for Pivotal US Clinical Trial
- CLEO Optimises Biomarker Panel Ahead of FDA Submission
Later from CLEO Diagnostics
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and 2026 Annual Report
- Change in Director's Interest Notice
- Notification of cessation of securities - COV
- Application for quotation of securities - COV
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics